Corporate Affairs in the Pharmaceutical Industry: How to Succeed in a Complex and Evolving Landscape

By the year 2030, global pharmaceutical demand is expected to grow more than 6% with expenditures approaching USD$1.5 trillion. Layered above this growth are complexities including new modalities, the increased reliance on artificial intelligence (AI) for drug discovery and development, improved manufacturing efficiency, more efficient and reliable supply chains and changing policies on product pricing, access and corporate governance, coupled with the requirements associated with reporting on environmental, social and governance (ESG) and diversity, equity and inclusion (DEI).

Corporate affairs leaders at the helm of pharmaceutical brands face a challenging task: connect a myriad of factors that are constantly changing and impacting the business differently over time, while also maintaining the confidence of investors, partners and other stakeholders. Through corporate affairs, the business seeks to build and protect reputation, cultivate trust, build an efficient, accurate and robust information conduit that may be relied upon by employees and business leaders alike and perform the daily work of corporate communications.

Download the full white paper here.